First In Ventures

ZeroTier is a developer of a software-defined networking solution that empowers users to create private networks for connecting a wide array of devices globally. Its platform facilitates direct, peer-to-peer connections while ensuring data privacy through end-to-end encryption. ZeroTier operates on a versatile open-source hybrid cloud architecture, making it compatible with various operating systems, including servers, cloud virtual machines, desktops, laptops, and mobile devices. The solution is designed for a diverse clientele, ranging from individual users to gamers, enterprises, and managed service providers, allowing for seamless and secure connectivity of wired and wireless devices and applications. Its user-friendly dashboard simplifies network management for all users.

Antithesis is a United States-based company that specializes in quality assurance software aimed at enhancing software reliability testing. The company's cloud platform automates this process by simulating environments that do not impact production systems. By continuously analyzing software behavior, Antithesis detects issues and reproduces problems in a fully deterministic setting. The platform introduces various faults, such as network retries and thread hangs, to identify rare errors and explore multiple outcomes. Furthermore, developers can test software under diverse conditions, specify validation properties, and trace issues back to their root causes. Antithesis facilitates efficient debugging by offering detailed tracking of system states and the capability to replay every moment leading to an issue, ultimately enabling clients to detect failures that occur under specific network, hardware, or timing conditions.

Pluton Biosciences is a bioscience research company that specializes in the testing and discovery of microbes for the development of various products, primarily focusing on biopesticides and pharmaceuticals. Utilizing an innovative platform, the company mines and clones microbes to generate a range of beneficial products aimed at enhancing biopesticides, crop protection, human health, and bioremediation. By harnessing the potential of bacteria, fungi, and viruses, Pluton Biosciences enables medical researchers and agricultural professionals to explore sustainable and all-natural solutions for various applications, contributing to advancements in both environmental and health-related sectors.

Neurolytic Healthcare Ltd. is a medical technology company based in Oxford, United Kingdom, specializing in the design, development, and manufacture of digital and genomic-based diagnostic tools and medical devices for migraine and related neurological disorders. Founded in 2016, the company focuses on personalized medicine by integrating genetic and biomarker data to enhance diagnosis and assist clinicians in determining optimal treatment strategies. Its product offerings include a diagnostic support tool, a pharmacogenetic test, and a mobile application designed to predict migraine events. By leveraging artificial intelligence, Neurolytic Healthcare aims to provide genomics-driven diagnostics and personalized treatment recommendations, helping patients find effective treatments while minimizing side effects and reducing the trial-and-error approach often associated with neurological care.

Yali Biosciences is a food tech company focused on utilizing synthetic biology and genomics to develop climate-smart and sustainable food options. The company operates a synthetic biology platform that leverages computational biology to design and produce specialized fats aimed at enhancing alternative dairy products. By prioritizing renewable resources, Yali Biosciences enables the food industry to create delicious and sustainable alternatives to traditional dairy, contributing to ecological responsibility within the sector.

AarogyaAI is an artificial intelligence-based software as a service company that specializes in diagnosing drug-resistant tuberculosis and other antimicrobial-resistant infections. The platform operates by analyzing a patient's DNA sequence, which is uploaded to its system. Utilizing advanced machine-learning algorithms, AarogyaAI delivers a comprehensive report detailing the drug susceptibility status of the patient within a few hours. This rapid and accurate diagnosis enables healthcare providers to prescribe effective drug combinations for treatment without delay, thereby improving patient outcomes in the management of infectious diseases.

Adlumin Inc. is a cybersecurity company that operates a security and compliance automation platform designed to identify threats, malfunctions, and IT operational failures. Founded in 2016 and based in Washington, D.C., the company collects and indexes data from various sources, including network traffic, web servers, and custom applications, to enhance security analytics. Adlumin's platform assists IT teams through security orchestration, automation, and machine learning, offering features such as One-Touch Compliance Reporting to streamline audit processes. The company focuses on serving mid-market organizations by providing advanced technology for threat detection, incident response, vulnerability management, and compliance support, ensuring that clients can effectively manage and mitigate cyber threats.

MEDIC Life Sciences is a biotechnology company based in the San Francisco Bay Area, specializing in cancer drug discovery. The company utilizes a proprietary CRISPR functional genomics platform to develop synergistic drug combinations for cancer treatment. By employing advanced 3D tumor models, MEDIC accurately captures tumor suppressor and oncogene phenotypes, systematically integrating CRISPR variants that mimic cancer mutations. This innovative approach allows for comprehensive measurement of drug associations with various mutations, ultimately enabling healthcare companies to create effective therapeutic options for treating tumors and other related diseases.

Pluton Biosciences is a bioscience research company that specializes in the testing and discovery of microbes for the development of various products, primarily focusing on biopesticides and pharmaceuticals. Utilizing an innovative platform, the company mines and clones microbes to generate a range of beneficial products aimed at enhancing biopesticides, crop protection, human health, and bioremediation. By harnessing the potential of bacteria, fungi, and viruses, Pluton Biosciences enables medical researchers and agricultural professionals to explore sustainable and all-natural solutions for various applications, contributing to advancements in both environmental and health-related sectors.

Gliknik Inc. is a biopharmaceutical company focused on developing therapies for patients with cancer and immune disorders. Founded in 2007 and based in Baltimore, Maryland, Gliknik's product portfolio includes GL-0817, aimed at preventing the recurrence of squamous cell carcinoma of the oral cavity, and GL-2045, which targets various autoimmune diseases such as immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and Myasthenia gravis. Additionally, the company develops GB-4542, an anti-CD20 monoclonal antibody therapy. Gliknik employs several innovative platforms, including an Immunomodulator Platform that utilizes off-the-shelf peptide drugs to enhance immune responses against cancer, the Stradomer Platform that creates drugs mimicking the efficacy of human intravenous immunoglobulin, and the Stradobody Platform, which produces compounds akin to monoclonal antibodies for tumor cell targeting. Through these initiatives, Gliknik aims to provide meaningful therapies that alleviate suffering for patients facing these challenging health conditions.

4baseCare is a company specializing in precision oncology solutions that utilize advanced genomic technologies to enhance cancer treatment. By analyzing the genetic profiles of patients, 4baseCare aims to identify targeted therapies that are both more effective and less harmful than conventional treatments. The company offers a range of services, including genomic testing, data interpretation, and personalized treatment recommendations, all designed to improve patient outcomes. Additionally, 4baseCare fosters collaborations with hospitals, research institutions, and pharmaceutical companies to advance cancer care and research. Their technology supports a patient-centric ecosystem, contributing to a curated database of genetic and clinical outcome information, thereby facilitating precision and personalized cancer treatments.

MultiplAI Health is a biotechnology company that focuses on enhancing disease detection through advanced blood screening tests. Utilizing RNA sequencing and artificial intelligence, the company analyzes a wide array of biomarkers in whole blood samples to identify complex diseases, including cardiovascular disorders and cancers. This innovative approach allows for universal remote screening, enabling both preventative assessments and post-treatment monitoring. The simplicity of a liquid biopsy means that tests can be conducted anywhere with just a blood sample, making them accessible and cost-effective compared to traditional diagnostic methods. By facilitating earlier detection of diseases in asymptomatic individuals, MultiplAI Health aims to improve patient prognoses and treatment strategies through more accurate diagnostic insights.

Parallel Health is a skin health company that uses genomics, the skin microbiome, and machine learning to offer end-to-end dermatology solutions. It develops a precision health platform that combines microbial genomics, big data, and AI to enable skin testing, personalized microbiome products, and custom prescriptions for consumers, patients, and clinicians, integrating derm telehealth, microbiome diagnostics, and data-driven skincare therapies to address diverse skin conditions with tailored treatments.

Mammoth Cyber is a provider of computer and network security solutions, specializing in an agentless zero-trust access system designed to enhance the security of remote, data, and web access. The company's innovative technology effectively blocks attacks from zero-day exploits while ensuring that enterprise data remains protected within its secure access service edge framework. This approach allows organizations to maintain full visibility and control over user interactions with applications, regardless of their existing architecture, platforms, or product portfolios. Mammoth Cyber's solutions are aimed at helping clients secure their digital environments and safeguard sensitive information.

Lassogen, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, California. The company focuses on the development of lasso peptides as a novel therapeutic modality aimed at addressing complex health challenges. Lassogen's research targets difficult receptors and encompasses a range of applications, including cancer treatment, autoimmunity, pain and inflammation management, as well as therapies for diseases associated with G protein-coupled receptors and ion channels. By leveraging advancements in synthetic biology, Lassogen seeks to unlock the potential of lasso peptides to create innovative medicines that can effectively diagnose and treat various conditions.

AarogyaAI is an artificial intelligence-based software as a service company that specializes in diagnosing drug-resistant tuberculosis and other antimicrobial-resistant infections. The platform operates by analyzing a patient's DNA sequence, which is uploaded to its system. Utilizing advanced machine-learning algorithms, AarogyaAI delivers a comprehensive report detailing the drug susceptibility status of the patient within a few hours. This rapid and accurate diagnosis enables healthcare providers to prescribe effective drug combinations for treatment without delay, thereby improving patient outcomes in the management of infectious diseases.